Anti-Mouse CD11a (Clone FD441.8) – Purified in vivo GOLD™ Functional Grade

Anti-Mouse CD11a (Clone FD441.8) – Purified in vivo GOLD™ Functional Grade

Product No.: C303

[product_table name="All Top" skus="C303"]

- -
- -
Clone
FD441.8
Target
CD11a
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
LFA-1α
Isotype
Rat IgG2b
Applications
FA
,
FC
,
N
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Cloned CTL B18 cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this FD441.8 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone FD441.8 recognizes an epitope on mouse CD11a.
Background
LFA-1α (CD11a) and CD18 are the Integrin alpha-L and beta-2 chains respectively that combine to form LFA-1, a glycoprotein and a member of the Integrin family. Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and for F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. The absence of LFA-1α or ß may induce LAD. The antigen contributes to natural killer cell cytotoxicity, and is involved in various immune phenomena such as leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. The CD11b/CD18 antigen is a heterodimeric surface glycoprotein on leukocytes and belongs to the ß2 integrin family. CD11b functions as a receptor for C3bi complement, clotting factor X, fibrinogen and ICAM-1. CD11c forms an α/ß heterodimeric glycoprotein (CD11c/CD18 complex) which belongs to the ß2 integrin family. The complex binds fibrinogen and reportedly serves as a receptor for iC3b and ICAM-1. During inflammatory responses, it mediates cell to cell interaction and is important in both monocyte adhesion and chemotaxis.
Antigen Distribution
CD11a is present on thymocytes, blood lymphocytes, bone marrow cells and certain lymphoma and macrophage-like cell lines.
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50)
Function
LFA-1 plays a central role in leukocyte intercellular adhesion.
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Costimulatory Molecules
.
Immunology
.
Signal Transduction

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone FD441.8 is a rat monoclonal antibody targeting mouse CD11a (LFA-1α) and is widely used in vivo to functionally block or deplete LFA-1 activity, most commonly to inhibit leukocyte adhesion, migration, and T cell activation in murine models.

Key in vivo applications in mice include:

  • Blocking LFA-1 (CD11a)-mediated leukocyte adhesion and trafficking: FD441.8 inhibits the interaction between LFA-1 and its ligands (ICAM-1, ICAM-2) to prevent leukocyte adhesion to vascular endothelium, thus impairing tissue infiltration during inflammation or immune responses.
  • Impairment of T cell–APC (antigen-presenting cell) interactions: LFA-1 is essential for immune synapse formation between T cells and APCs. Blocking CD11a with FD441.8 can dampen T cell activation and cytotoxicity in vivo, offering insight into immune regulation mechanisms.
  • Inhibition of dendritic cell and other leukocyte migration: Functional blockade of LFA-1 can be used to study the requirement for integrin-mediated motility of dendritic cells and other immune cell subsets in models of infection, autoimmunity, and cancer.
  • Prevention or modulation of graft-versus-host disease and autoimmune conditions: By limiting lymphocyte infiltration into tissues, FD441.8 enables studies of immune-mediated tissue damage and therapeutic strategies in transplant and autoimmune models.

Additional standard uses:

  • In vivo depletion or blockade protocols for functional immune studies: FD441.8 is routinely used as a blocking antibody in vivo for functional analysis of the CD11a pathway, with recommended low endotoxin preparations for animal injections.
  • Controls for mechanistic studies in inflammation and immunology research.

Less common or indirect applications:

  • Allograft and transplant rejection studies: Modulating T cell infiltration to allografts.
  • Tumor immunology: Modulating antitumor T cell responses, especially cytotoxic T lymphocyte recruitment.

Experimental considerations: Successful use in vivo depends on optimizing dose, timing, and route of administration for each experimental design, and using functionally validated, low-endotoxin antibody preparations.

Summary Table: Common In Vivo Applications of Clone FD441.8 in Mice

ApplicationPurposeReference
Blocking leukocyte adhesion/migrationStudy inflammation, trafficking, immune cell recruitment
Inhibiting T cell activation/cytotoxicityModulate immunity, study immune synapse, transplant rejection
Inhibiting dendritic cell migrationAnalyze requirements for DC motility and trafficking
In vivo blockade in autoimmune or infection modelsModulate disease, dissect mechanisms
Controls for antibody-based functional in vivo depletion/blockadeMechanistic research in immunology

Note: While clone FD441.8 is validated for in vivo functional inhibition, depletion of cells expressing CD11a is not a common or efficient application due to its mode of action as a blocking rather than depleting antibody. For depleting certain leukocyte subsets, depletion-specific clones or toxin-conjugated antibodies are preferable.

References marking the main points:

Based on the search results, FD441.8 (an anti-mouse CD11a/LFA-1α antibody) is commonly used in combination with several other antibodies and proteins in research applications:

Co-stimulation Blockade Studies

FD441.8 is frequently paired with anti-CD154 monoclonal antibodies in co-stimulation blockade protocols. In pancreatic islet xenograft survival studies, researchers used an equal mixture of FD441.8 and MR-1 (an anti-CD154 antibody) to achieve subtherapeutic co-stimulation blockade. This combination targets different aspects of the immune response by blocking both LFA-1-mediated adhesion and CD154-dependent costimulatory signals.

Lymphocyte Function Studies

In lymphocyte homing and trafficking research, FD441.8 has been used alongside other adhesion molecule antibodies including anti-CD4 (clone GK1.5), anti-CD8 (clone 53-6.7.2), and anti-α4 (clone PS/2). This combination allows researchers to comprehensively examine the roles of different integrins and surface markers in lymphocyte migration to specific tissues like bronchus-associated lymphoid tissue.

Natural Pairing with Ligands

Given that FD441.8 targets LFA-1α (CD11a), it naturally functions in systems involving LFA-1's binding partners. The antibody is relevant in studies examining interactions with ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), which are the natural ligands for LFA-1. Additionally, since CD11a combines with CD18 (integrin beta-2 chain) to form the complete LFA-1 heterodimer, studies may examine both components together.

Clone FD441.8 is a monoclonal antibody that targets mouse CD11a, also known as LFA-1α, which plays a crucial role in cell adhesion and immune responses. Here are the key findings from its citations in scientific literature:

Key Findings

  1. Target Specificity: Clone FD441.8 specifically recognizes an epitope on mouse CD11a, an antigen present on thymocytes, blood lymphocytes, bone marrow cells, and certain lymphoma and macrophage-like cell lines.

  2. Applications: This antibody is used in various applications, including blocking, immunohistochemistry, immunoprecipitation, and in situ hybridization.

  3. Immune Response Modulation: The FD441.8 antibody has been used in studies to modulate immune responses. For example, it has been employed to block LFA-1 interactions, which are critical for leukocyte adhesion and migration.

  4. Mechanism of Action: Studies have shown that blocking LFA-1 with FD441.8 can inhibit the early infiltration of endogenous memory T cells, indicating its potential in manipulating immune cell trafficking.

  5. Impact on T Cell Functions: The antibody has been used to investigate the role of LFA-1 in T cell adhesion and antigen presentation. It was observed that FD441.8 could block antigen presentation under certain conditions, highlighting the complex role of LFA-1 in immune interactions.

Conclusion

Clone FD441.8 is a valuable tool in immunological research, particularly in studies involving LFA-1 and its role in immune cell adhesion and trafficking. Its applications range from basic research to potential therapeutic interventions, where modulating immune responses is essential.

Dosing regimens of clone FD441.8 (anti-LFA-1) in mouse models typically involve intraperitoneal injections of the antibody at a dose of 250 μg per mouse on specific days post-transplant (days 0, 2, 4, and 6), followed by biweekly injections until 3 months post-transplantation. Most published protocols use this antibody as part of multi-agent immune suppression to enable transplantation success, particularly in strains resistant to xenograft acceptance, such as C57BL/6 mice.

  • Standard regimen: 250 μg/mouse intraperitoneally on days 0, 2, 4, and 6, with biweekly boosters up to 3 months.

Regimen variations may depend on:

  • Mouse strain and immunological challenge: For example, highly immunocompetent strains like C57BL/6 may require adjunctive immunosuppressants (e.g., FTY720) in addition to anti-LFA-1 for optimal xenograft survival.
  • Study aim (transplantation vs. cell labeling/in vitro): In cell labeling or in vitro flow-based assays, FD441.8 may be used at considerably lower concentrations, such as 50 μg/mL for staining at 4°C for 30 minutes. This is not directly comparable to in vivo dosing for functional blockade.

Additional relevant details:

  • Injection route is typically intraperitoneal.
  • Combined regimens frequently pair FD441.8 with other antibodies (anti-CD48, CTLA4-Ig) or pharmacologic agents (FTY720, rapamycin, FK506, MMF), with dosing and schedule adapted for each component.
  • No substantive data is available from search results on varying FD441.8 dosing in tumor versus transplantation or infection models. Most published dosing schedules focus on transplantation and immune tolerance research.

In summary, while FD441.8 dosing in mouse models is usually 250 μg/mouse i.p. given repeatedly over several weeks to months, variations reflect study-specific goals, mouse strain immunogenicity, and combination with other immunosuppressive agents.

References & Citations

1. Suratt, Benjamin T. et al. (2009) J Immunol.182(1): 604–612. PubMed
2. Wuthrich, R. P. et al. (1991) Cell Immunol. 144:22
3. Sanchez-Madrid, F. et al. (1983) J. Exp. Med. 158(20):586
4. Pont, S. et al. (1986) J. Immunol. 136(10):3750
FA
Flow Cytometry
N
General Western Blot Protocol

Certificate of Analysis

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.